FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060403425> ?p ?o ?g. }

• W2060403425 endingPage "567" @default.
• W2060403425 startingPage "557" @default.
• W2060403425 abstract "This prospective phase II parallel-group, double- blind, randomized, placebo-controlled clinical trial was meant to evaluate the effect of a humanized monoclonal anti-L-selectin antibody (aselizumab) on the posttraumatic inflammatory response in severely injured patients. To be eligible for the study, patients had to have sustained a trauma due to a blunt or penetrating injury, which involved at least two organ systems according to the Abbreviated Injury Scale (AIS) resulting in a total Injury Severity Score (ISS) of ≥ 25. Included patients (n = 84) received either placebo or 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg of aselizumab within 6 h of the traumatic event. Parameters representing the posttraumatic inflammatory response were monitored for 10 days, patients’ general records were monitored for 14 days and discontinuously until day 42. The incidence of multiple organ failure (MOF) defined as a median value of the total Goris MOF score of ≥ 5 on ≥ 2 consecutive days within the first 14 days was not significantly different for the placebo and the 0.5-mg/kg, 1.0-mg/kg, and 2.0-mg/kg groups. The cytokine interleukin-(IL-)6 and IL-10 serum levels as well as neutrophil elastase serum concentrations revealed the well-described posttraumatic acute response which resolved from day 3 after trauma in all four study groups. Also complement factor C3a and procalcitonin followed the same pattern. There were no statistically significant differences between placebo and patients having received anti-L-selectin at different dosages. For all of the measured variables, IL-6, IL-10, elastase, C3a and procalcitonin, there were only a few trends but no significant differences between all study groups indicating that the effect of the administered anti-L-selectin antibody on the posttraumatic inflammatory response was similar to that of placebo." @default.
• W2060403425 created "2016-06-24" @default.
• W2060403425 creator A5005302803 @default.
• W2060403425 creator A5030343627 @default.
• W2060403425 creator A5039164555 @default.
• W2060403425 creator A5047408505 @default.
• W2060403425 creator A5048014739 @default.
• W2060403425 creator A5055531816 @default.
• W2060403425 date "2005-11-01" @default.
• W2060403425 modified "2023-09-27" @default.
• W2060403425 title "The Effect of Anti-L-Selectin (Aselizumab) on the Posttraumatic Inflammatory Response in Multiply Traumatized Patients" @default.
• W2060403425 cites W1525310086 @default.
• W2060403425 cites W1803681061 @default.
• W2060403425 cites W1966075924 @default.
• W2060403425 cites W1982338503 @default.
• W2060403425 cites W1989986582 @default.
• W2060403425 cites W1992859813 @default.
• W2060403425 cites W1996147623 @default.
• W2060403425 cites W1999624627 @default.
• W2060403425 cites W2004536137 @default.
• W2060403425 cites W2010047414 @default.
• W2060403425 cites W2020039186 @default.
• W2060403425 cites W2021282817 @default.
• W2060403425 cites W2025579398 @default.
• W2060403425 cites W2025756876 @default.
• W2060403425 cites W2031308244 @default.
• W2060403425 cites W2040177117 @default.
• W2060403425 cites W2048529106 @default.
• W2060403425 cites W2055877452 @default.
• W2060403425 cites W2058329893 @default.
• W2060403425 cites W2059502318 @default.
• W2060403425 cites W2065608529 @default.
• W2060403425 cites W2085137385 @default.
• W2060403425 cites W2086584071 @default.
• W2060403425 cites W2090456626 @default.
• W2060403425 cites W2093258158 @default.
• W2060403425 cites W2114922744 @default.
• W2060403425 cites W2122106089 @default.
• W2060403425 cites W2128256270 @default.
• W2060403425 cites W2143762038 @default.
• W2060403425 cites W2161470156 @default.
• W2060403425 cites W2162906577 @default.
• W2060403425 cites W2415274192 @default.
• W2060403425 doi "https://doi.org/10.1007/s00068-005-1066-4" @default.
• W2060403425 hasPublicationYear "2005" @default.
• W2060403425 type Work @default.
• W2060403425 sameAs 2060403425 @default.
• W2060403425 citedByCount "2" @default.
• W2060403425 countsByYear W20604034252022 @default.
• W2060403425 crossrefType "journal-article" @default.
• W2060403425 hasAuthorship W2060403425A5005302803 @default.
• W2060403425 hasAuthorship W2060403425A5030343627 @default.
• W2060403425 hasAuthorship W2060403425A5039164555 @default.
• W2060403425 hasAuthorship W2060403425A5047408505 @default.
• W2060403425 hasAuthorship W2060403425A5048014739 @default.
• W2060403425 hasAuthorship W2060403425A5055531816 @default.
• W2060403425 hasBestOaLocation W20604034251 @default.
• W2060403425 hasConcept C10936531 @default.
• W2060403425 hasConcept C120665830 @default.
• W2060403425 hasConcept C121332964 @default.
• W2060403425 hasConcept C126322002 @default.
• W2060403425 hasConcept C141071460 @default.
• W2060403425 hasConcept C142724271 @default.
• W2060403425 hasConcept C162156334 @default.
• W2060403425 hasConcept C190385971 @default.
• W2060403425 hasConcept C204787440 @default.
• W2060403425 hasConcept C27081682 @default.
• W2060403425 hasConcept C2776914184 @default.
• W2060403425 hasConcept C2778384902 @default.
• W2060403425 hasConcept C2781246285 @default.
• W2060403425 hasConcept C3017944768 @default.
• W2060403425 hasConcept C3020196126 @default.
• W2060403425 hasConcept C61511704 @default.
• W2060403425 hasConcept C71924100 @default.
• W2060403425 hasConcept C85004164 @default.
• W2060403425 hasConcept C90924648 @default.
• W2060403425 hasConcept C99454951 @default.
• W2060403425 hasConceptScore W2060403425C10936531 @default.
• W2060403425 hasConceptScore W2060403425C120665830 @default.
• W2060403425 hasConceptScore W2060403425C121332964 @default.
• W2060403425 hasConceptScore W2060403425C126322002 @default.
• W2060403425 hasConceptScore W2060403425C141071460 @default.
• W2060403425 hasConceptScore W2060403425C142724271 @default.
• W2060403425 hasConceptScore W2060403425C162156334 @default.
• W2060403425 hasConceptScore W2060403425C190385971 @default.
• W2060403425 hasConceptScore W2060403425C204787440 @default.
• W2060403425 hasConceptScore W2060403425C27081682 @default.
• W2060403425 hasConceptScore W2060403425C2776914184 @default.
• W2060403425 hasConceptScore W2060403425C2778384902 @default.
• W2060403425 hasConceptScore W2060403425C2781246285 @default.
• W2060403425 hasConceptScore W2060403425C3017944768 @default.
• W2060403425 hasConceptScore W2060403425C3020196126 @default.
• W2060403425 hasConceptScore W2060403425C61511704 @default.
• W2060403425 hasConceptScore W2060403425C71924100 @default.
• W2060403425 hasConceptScore W2060403425C85004164 @default.
• W2060403425 hasConceptScore W2060403425C90924648 @default.
• W2060403425 hasConceptScore W2060403425C99454951 @default.
• W2060403425 hasIssue "6" @default.

• next